Update: April 2020
COVID-19 and Diabetes Webinars
Prof. Chantal Mathieu and Prof. Alice Cheng discuss management priorities for Type 2 diabetes patients amidst the COVID 19 pandemic, including key considerations and strategies for remote consultations.
Click above to Play the Webinar Section from Prof Chantal Mathieu (April 8, 2020)
Click above to Play the Webinar Section from Prof Alice Cheng (April 8, 2020)
Click above to Play the Webinar Section with the Q&A (April 8, 2020)
Click above to Play the Webinar Section with the second Q&A (April 15, 2020)
Click on the topics below to learn more:
Some medications need to be temporarily discontinued when patients are ill and unable to maintain adequate fluid intake. These include sulfonylureas, ACE inhibitors, diuretics, metformin, and SGLT2 inhibitors (SADMANS*).
*SADMANS – Sulfonylureas, Agiotensin enzyme inhibitors, Diuretics, Metformin, Angiotensin receptor blocker, Non-steroidal anti-inflammatory agenty, Sodium glucose linked transport 2 inhibitors.
Guidance has been provided by ACC, HFSA, AHA (and ESC) regarding use of ACE inhibitors, ARBs, or other RAAS inhibitors given absence of experimental or clinical data in COVID-19 or among COVID-19 patients with a history of cardiovascular disease treated with such agents
“In this page Boehringer Ingelheim has compiled and summarized some general information about COVID-19 as a service. With respect to linked information from third parties, we have selected the sources carefully for credibility but cannot make any representations and/ or warranties with regard to their accuracy or the completeness of the provided and/ or selected information.”
“This information shall only serve for your background information and cannot replace consultation through a physician. Please make sure that you discuss any questions and/ or concerns with regard to your disease with your physician. Please also make sure that you always follow your local rules with regard to behavioral measures.”